---
title: "Skyrizi (risankizumab-rzaa), all indications: Specific populations questions"
description: "Specific populations questions on Skyrizi (risankizumab-rzaa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is Skyrizi safe during pregnancy? Can Skyrizi be used while breastfeeding? Is Skyrizi safe and effective in adults 65 and older? Has Skyrizi been studied in patients with kidney or liver impairment? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/skyrizi/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa), all indications: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)

## Specific populations

<a id="skyrizi-pregnancy"></a>

### Is Skyrizi safe during pregnancy?

> “Available pharmacovigilance and clinical trial data with risankizumab use in pregnant women 
> are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other 
> adverse maternal or fetal outcomes. Although there are no data on risankizumab-rzaa, 
> monoclonal antibodies can be actively transported across the placenta, and SKYRIZI may cause 
> immunosuppression in the in utero-exposed infant.”

Source: [SKYRIZI: Prescribing information, page 14, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=14)

> “Pregnancy Exposure Registry 
> There is a pregnancy exposure registry that monitors outcomes in women who become pregnant 
> while treated with SKYRIZI. Patients should be encouraged to enroll by calling 1-877-302-2161 or 
> visiting http://glowpregnancyregistry.com.”

Source: [SKYRIZI: Prescribing information, page 14, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=14)

<a id="skyrizi-breastfeeding"></a>

### Can Skyrizi be used while breastfeeding?

> “There are no data on the presence of risankizumab-rzaa in human milk, the effects on the 
> breastfed infant, or the effects on milk production. Endogenous maternal IgG and monoclonal 
> antibodies are transferred in human milk. The effects of local gastrointestinal exposure and 
> limited systemic exposure in the breastfed infant to risankizumab-rzaa are unknown. The 
> developmental and health benefits of breastfeeding should be considered along with the mother's 
> clinical need for SKYRIZI and any potential adverse effects on the breastfed infant from 
> SKYRIZI or from the underlying maternal condition.”

Source: [SKYRIZI: Prescribing information, page 16, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=16)

<a id="skyrizi-older-adults"></a>

### Is Skyrizi safe and effective in adults 65 and older?

> “Of the 7,144 subjects exposed to SKYRIZI, a total of 685 were 65 years and older (243 subjects 
> with plaque psoriasis, 246 subjects with psoriatic arthritis, 93 subjects with Crohn’s disease and 
> 103 subjects with ulcerative colitis), and 73 subjects were 75 years and older.  
> Clinical studies of SKYRIZI, within each indication, did not include sufficient numbers of 
> subjects 65 years of age and older to determine whether they respond differently from younger 
> adult subjects. 
> No clinically meaningful differences in the pharmacokinetics of risankizumab-rzaa were 
> observed based on age [see Clinical Pharmacology (12.3)].”

Source: [SKYRIZI: Prescribing information, page 17, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=17)

<a id="skyrizi-kidney-liver-impairment"></a>

### Has Skyrizi been studied in patients with kidney or liver impairment?

> “No studies have been conducted to determine the 
> effect of renal or hepatic impairment on the pharmacokinetics of risankizumab-rzaa.”

Source: [SKYRIZI: Prescribing information, page 20, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=20)

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): All indications](https://www.evicenter.com/medical-information/skyrizi)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/skyrizi/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/skyrizi/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi/storage-and-supply)
